Th e life expectancy of patients with cystic fi brosis (CF) has improved greatly over the last 3 decades, with the median predicted age of survival increasing from 27 years in 1986 to 41 years in 2012. [1] [2] [3] Th is improvement has been attributed in part to the establishment of regionalized care in CF specialty centers. [4] [5] [6] CF centers provide coordinated, multidisciplinary care and support services to help patients and their families navigate the labor-intensive and complex therapy regimens required to maintain lung health. However, there remains considerable concern regarding ethnic disparities in health outcomes, which may be related to diff erential care access or capacity to adhere to these complex regimens. [7] [8] [9] For other chronic illnesses, patients of Hispanic ethnicity, particularly those with limited English profi ciency or limited health literacy, are particularly susceptible to outcome disparities. [10] [11] [12] Th e relative proportion of Hispanic patients receiving a diagnosis of CF has been rising over time (7% in 2010), 2 as the size of the general Hispanic population and awareness of the prevalence of CF in Hispanic populations have risen. 13 California has a large Hispanic population (37.6% of the state's population in 2010), 14 and it has the largest number and highest proportion of Hispanic patients with CF, making it an optimal place to study this subpopulation.
Hispanic patients with CF are a potentially vulnerable subpopulation because of an increased prevalence of risk factors associated with worse health outcomes. Th e health trajectory of Hispanic patients with CF, in contrast to patients of non-Hispanic ethnicity with CF, has not been well described. In this study, we aim to characterize the patterns of mortality and risk factors for poor health outcomes among Hispanic patients with CF over the last 20 years and in comparison with the concurrent non-Hispanic patient population with CF.
Materials and Methods
Th is is a retrospective analysis of the CF Foundation Patient Registry (CFFPR) of California residents (N 5 4387). Th e CF Foundation approved the use of the registry data. Th e Stanford University institutional review board, panel on human subjects in medical research , approved the study protocol (No. 19908).
Th e CF Foundation has stored health information from patients seen at accredited centers since 1966 and maintains patient data from 1986. 15 Each patient's ethnicity has been collected by parental or self-report since 1991. Th us, the study period was January 1, 1991, to December 31, 2010 . Inclusion criteria included a childhood diagnosis ( Յ 18 years of age) of CF during the study period to control for left censoring (events or death prior to entry into the study). Patients who were missing insurance status (n 5 5) were excluded ( Fig 1 ) .
Th e primary outcome was death. Subjects were censored at the time of lung transplant, loss to follow-up, or end of the observation period. Other health outcomes included FEV 1 , a validated pulmonary health parameter in CF and recorded as the % predicted value (% pred) based on normative data [15] [16] [17] ; BMI; and z score, adjusted for patient's age and sex.
Th e primary predictor of interest was ethnicity, Hispanic or non-Hispanic, by parental or self-report. Secondary predictors were identifi ed a priori based on a review of previous literature on the clinical, biologic, and social factors most likely to mediate or confound any relationship between ethnicity and health outcomes.
Clinical and biologic factors assessed included age and year of diagnosis, 18 sex, 19, 20 CF transmembrane conductance regulator (CFTR) genotype, 19, 21 infections with Pseudomonas aeruginosa or Burkholderia cepacia , 22, 23 and CF-related diabetes mellitus (CFRDM). 24 CFTR genotype severity was categorized into one of fi ve functional classes proposed by Welsh et al. 25 Th e mutations were further classifi ed into three groups: "high" or "low" disease risk according to the scheme proposed by McKone et al 21 and "unclassifi ed" disease risk for mutations with unknown functional class. Infection with Pseudomonas or burkholderia was characterized as dichotomous (never/ever) and by age at fi rst acquisition; earlier age at acquisition is associated with worse prognosis. 23, 26, 27 Diagnosis of CFRDM was characterized as dichotomous (never/ever) and age at diagnosis. 24 Social factors assessed included public insurance status, median household income, 8, 19 and access to subspecialty care. 4 Public insurance (Medicare, Medicaid, state special needs program, and/or Indian Health Services) was categorized as dichotomous (never/ever). Neighborhood median household income was estimated by the subject's mode residential ZIP code using the Claritas, Inc demographic database, 28 and was categorized on the basis of the federal poverty line (FPL) designation for 2004 ($18,850 for a family of four). Access to subspecialty care was defi ned by the mean number of outpatient visits to CF Foundation-accredited centers per year of observation. Optimal access to subspecialty care was defi ned as three or more outpatient clinic visits per year. 29, 30 We performed time-to-event (survival) analysis with time as years since diagnosis to avoid left censoring (bias of events/deaths prior to entry into the study), because the study cohort is defi ned as diagnosis with CF and enrollment in the CFFPR. We estimated cause-specifi c hazard ratios (HRs) of death in Hispanics vs non-Hispanics using multivariable Cox proportional hazard models, adjusting for the previously mentioned covariates. Assessing the assumption of proportionality for all covariates and time-dependent interaction, we found that sex was in violation and as our fi nal model we present a stratifi ed cox model on sex. Categorical variables were compared by x 2 or Fisher exact tests. Continuous variables were compared by t tests or Mann-Whitney U test and Wilcoxon two-sample test. To assess whether there was an eff ect of ethnicity on decline of FEV 1 and BMI by age, we compared randomeff ects models of FEV 1 and BMI by age and ethnicity with and without interaction of age and ethnicity. Models were compared using sum of squares, corrected Akaike's information criteria, and F test.
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Results
A total of 1,719 California residents with CF received the diagnosis during or aft er 1991 and before 18 years of age. Hispanic patients made up 28.2% (n 5 485) ( Fig 1 ) . Compared with non-Hispanic patients with CF, a slightly greater proportion (22.9% vs 17.1%, P 5 .0056) Figure 1 [AQ17]
of Hispanic patients received the diagnosis aft er introduction of universal newborn screening in California in June 2007 ( Table 1 ) .
Mortality
During the study period, the overall unadjusted mortality rate for the entire sample was 4.9% (n 5 85). Mortality in Hispanic patients was 9.1% (n 5 44), whereas mortality in non-Hispanic patients was 3.3% (n 5 41) ( Table 1 ) . Th e unadjusted risk ratio for mortality in Hispanic patients was 2.73. Th e mean age at death for Hispanic patients and non-Hispanic patients was not statistically diff erent (11.7 years [SD, 5.2] years vs 13.4 years [SD, 5.8], P 5 .1775). Th e leading cause of death in both groups was reported as respiratory or cardiorespiratory. Kaplan-Meier survival analysis showed that Hispanic patients had lower survival rate 18 years aft er diagnosis (75.9% vs 91.5%, P , .0001) ( Fig 2 ) . To assess the potential impact of diff ering transplant rates, we analyzed cumulative incidence curves for competing events of death and lung transplant, which showed no diff erence in incidence of lung transplant (data not shown).
Adjusted Analyses
A stratifi ed multivariable Cox proportional hazards model revealed that Hispanic patients had 2.81 times the rate of death of non-Hispanic patients (95% CI,1.70-4.63) aft er adjusting for year of diagnosis, age at diagnosis, public insurance, neighborhood median household income, bacterial infection, CFRDM diagnosis, and CFTR genotype ( Table 2 ). Low neighborhood median household income (two to four times FPL) was also independently associated with a higher rate of death (adjusted HR, 2.93; 95% CI, 1.04-8.24). Compared with patients with two high-risk CFTR mutations, patients who had two CFTR alleles of unclassifi ed disease risk (adjusted HR, 2.61; 95% CI, 1.25-5.43) or were not genotyped at all (adjusted HR, 3.28; 95% CI, 1.68-6.43) had a higher rate of death. Neither Pseudomonas or burkholderia infection nor CFRDM diagnosis was independently associated with an increased rate of death.
Lung Function and BMI
At 6 years of age (the fi rst age at which lung function can be measured and collected reliably), the mean FEV 1 for Hispanic patients was lower than for non-Hispanic patients (77% pred [SD 23% pred] vs 89% pred [SD 20% pred], P , .0001). However, the yearly rate of decline in FEV 1 between Hispanic and non-Hispanic patients was not diff erent ( Fig 3A ) . BMI as a proxy for nutrition plotted by age was not diff erent between Hispanic and non-Hispanic patients ( Fig 3B ) .
Clinical and Biologic Factors
Th ere were no signifi cant diff erences in age at diagnosis and distribution of sex between Hispanic and non-Hispanic patients. Th e median age at diagnosis for the entire cohort was 5.8 months (interquartile range, 0.9-38.3).
Diff erent CFTR genotype patterns were observed between Hispanic and non-Hispanic patients ( Table 3 ) . (50.3%) of at least one CFTR allele of unclassifi ed risk, compared with 28.1% in non-Hispanic patients ( Table  1 ) . Of note, 6.3% of patients in the registry did not have CFTR genotype data, and this was not signifi cantly different between groups ( x 2 P 5 .19).
Although there was no diff erence in the overall incidence of infection with Pseudomonas or burkholderia between Hispanic and non-Hispanic patients, Hispanic patients reported a younger age at fi rst acquisition for both organisms ( Table 1 ) . Th ere was no diff erence in incidence of CFRDM between the two groups, but the mean age at diagnosis with CFRDM was 1 year younger in Hispanic patients than in non-Hispanic patients (13.4 years (SD, 4.3) and 14.9 years (SD, 4.4), respectively; P 5 .04).
Social Factors and Health-care Access
Hispanic patients were more likely to ever have public health insurance and a greater average percent time with public insurance per time in the registry ( Table 1 ) . Nearly a third of the Hispanic patients lived in neighborhoods with high rates of poverty (estimated neighborhood median household income of less than two times FPL). Th ere was no diff erence in health-care access (mean number of clinic visits per 12 months or suboptimal use) at outpatient CF centers between Hispanic and non-Hispanic patients ( Table 1 ) .
Discussion
Although the median lifespan for CF has improved over the last 20 years, we found signifi cantly higher rates of mortality among patients of Hispanic ethnicity with CF. By Cox proportional hazards modeling, Hispanic patients had 2.81 times the mortality rate of Figure 3 -A Stratifi ed by sex. Model is adjusted for ethnicity, CFTR risk severity, Pseudomonas infection, burkholderia infection, CF-related diabetes , year of diagnosis, age at diagnosis (mo), public insurance, and neighborhood median household income. HR 5 hazard ratio. See Table 1 legend for expansion of other abbreviations.
death compared with non-Hispanic patients, and this remained signifi cant and independent of the biologic, diagnostic, clinical, and social factors that are known to be associated with mortality in CF. Th is fi nding is congruent with prior published data of mortality rates in ethnic minority groups, 19 but this study further explores the specifi c risk factors associated with mortality.
Disease severity and mortality is a result of complex relationships among multiple factors along a patient's life course. 32, 33 In this study, we attempted to investigate these complex mechanisms using the data available in the CFFPR. Hispanic and non-Hispanic patients have diff erent CFTR genotype patterns. Many of the CFTR genotypes seen in Hispanic patients do not have functional or risk classifi cations. Th is has future implications [AQ20]
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because new therapies in CF are based on biologic function or protein traffi cking of the CFTR molecule, which is based on predictions from the CFTR genotype. 34 Unknown CFTR genotype was independently associated with increased mortality risk. Th is fi nding may be due to more severe clinical phenotype associated with not needing to be genotyped for diagnosis (data not shown).
A higher proportion of Hispanic patients than nonHispanic patients lived in poor neighborhoods. Prior research has shown that median family income is independently associated with mortality. 8 Th e adjusted analysis included neighborhood median household income and did not completely attenuate the residual diff erence in mortality rate observed for Hispanic patients. Poverty and social class likely contribute to the diff erences in health outcomes but could not be completely accounted for in the data available. [35] [36] [37] Although there was no diff erence in access and use of CF center care, age at diagnosis, and nutritional status, lung function measured by FEV 1 was signifi cantly lower for Hispanic patients than for non-Hispanic patients at 6 years of age, which is compatible with the one cross-sectional study of Hispanic patients with CF. 38 However, we observed no ethnic diff erences in yearly rate of decline of FEV 1 or BMI. It is not clear if the 12% pred point difference between the two groups is adequate to explain the diff erence in mortality rates observed. Future studies will need to investigate the causes of the diff erence in lung function at fi rst measurement between the two groups, which may be a result of diff erences in normative data for ethnicity, care in the fi rst 6 years of life, severity of pulmonary exacerbations, inherent CF disease severity, or a combination of these factors.
Although there was no diff erence in the prevalence of CF complications, Hispanic patients were diagnosed with Pseudomonas or burkholderia infection or CFRDM 1-3 years before their non-Hispanic counterparts. Lower lung function and earlier incidence of CF complications are likely important contributors to the increased rate of mortality observed in Hispanic patients. Future studies are necessary to investigate this further. Although there was no diff erence in access to CF centers, there may be contributing individual factors such as adherence to treatment regimens, self-management, culture, health literacy, and English profi ciency. 11, 12, [39] [40] [41] Patients with shared ethnicity, language, and/or culture provide a unique opportunity for targeted intervention to improve health outcomes. Our fi ndings of increased mortality in Hispanic patients, diff erences in baseline lung function, and early incidence of CF complications suggest a promising opportunity for the development of preventative and management strategies that can be both cost eff ective and more culturally appropriate for Hispanic patients and families living with CF.
Limitations
Th is study and its fi ndings are subject to the biases common to studies of clinical registries. Selection bias results from studying the CFFPR, which requires subjects to have access to CF subspecialty care. Misclassification bias can occur from self-reported ethnicity. Measurement bias may have aff ected assessment of social factors, particularly family income, which was estimated ecologically by ZIP code. As a result, we are unable to capture all the determinants of health, such as discrimination and bias, quality of care, physical environment, and individual factors (health literacy, English profi ciency).
Hispanic ethnicity is a sociopolitical construct, heavily confounded by socioeconomic status and cultural identity. 42, 43 Social and biomedical scientists have cautioned against the classifi cation of patients by ethnicity and race in biomedical research because of reifying race. [42] [43] [44] [45] However, patients of Hispanic ethnicity have been described as experiencing a variety of other health disparities, oft en related to diff erences in health-care access, acculturation, and language-related barriers to care. [10] [11] [12] Th is study adds to the literature to support the existence of health disparities for patients of Hispanic ethnicity; however, the generalizability is limited because of the specifi c disease progression and management experienced by patients with CF.
Accuracy of age at fi rst detection of airway organisms in the CFFPR is dependent on the sensitivity of detection and diagnosis of organisms in individual subjects, which is aff ected by culture type and microbiology techniques. 46 However, there is no reason for diff erential sensitivity of microbiology diagnosis between the two study groups.
Implications
Th is study demonstrates that Hispanic ethnicity is a risk factor for increased mortality among patients with CF. In addition, neighborhood poverty and unclassifi ed or unknown CFTR genotype are associated with an increased rate of mortality. Th e key strength of this study was the size and time period covered by this fi rst eff ort to understand the ethnic, social, and biologic epidemiology of CF-related mortality. As mentioned, the relationship of ethnicity and mortality is likely multifactorial and complex. Some health policies adopted in the last 10 years, such as universal newborn screening, have the potential to positively aff ect the health of patients with CF. Future analyses should also consider the impact of these programs on the observed ethnic disparities in health outcomes and mediators.
Conclusions
Th e Hispanic ethnicity-specifi c disparity in mortality rates among people with CF has persisted despite improvements in the care of all patients with CF. With anticipated continued growth in the overall Hispanic population and the disproportionate growth of the Hispanic population within the CF community, this ethnic disparity in mortality rates should give us pause. Understanding the mechanisms for the increased mortality rate among Hispanics is necessary to improve the health of all patients with CF.
